Compare ADMA Biologics Inc (ADMA) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Global X SuperDividend ETF — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Global X SuperDividend ETF trades at $24.78. The key difference: Global X SuperDividend ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | SDIV | |
|---|---|---|
Market Cap | $2.18B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $20.38 | $26.34 |
52-Week Low | $7.60 | $22.90 |
Enterprise Value | $2.25B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
SDIV trades at $24.81, up 1.02% with a neutral technical signal. The ETF maintains a consistent dividend payout of $0.18 monthly, providing a high yield for income-focused investors. Recent news highlights SDIV's role in diversification away from AI-heavy portfolios, with Seeking Alpha upgrading it to a buy rating citing attractive valuation and 9.29% yield. Technical indicators show mixed signals with bearish moving averages but neutral oscillators.
SDIV offers exposure to global high-dividend stocks with minimal tech exposure, appealing during market volatility. Key risks include concentration in financials and energy sectors, interest rate sensitivity, and geopolitical factors affecting dividend sustainability. The fund's 6% yield target provides income stability but requires monitoring of underlying holdings' financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
